Xenova Group Limited, a fully-owned subsidiary of Celtic Pharma Development plc, is a UK-based biopharmaceutical company focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. The Company has a broad pipeline of drug candidates in clinical development including a novel programme for the treatment of high-grade glioma, TransMIDTM. Details of all the programmes can be found in the Drug Candidates section.
| Contact Details: |
| 957 Buckingham Avenue |
| Slough |
| Berkshire |
| SL1 4NL |
| United Kingdom |
| Tel: | 44 (0) 1753 706600 |
| Fax: | 44 (0) 1753 706607 |
| Email: | info@xenova.com |
| WWW: | www.KSBIOMEDIX.COM/
|
| |
Recent Publications by Xenova: |  |
Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma.
XR5944 (MLN944) is a novel bis-phenazine currently in phase I clinical... | 17th December, 2005
| Xenova
| Anticancer Drugs. 2005 Oct;16(9):945-51.
|
Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
XR5944 (MLN944), a novel bis-phenazine, has demonstrated potent cytotoxic... | 25th March, 2005
| Xenova Ltd, 957 Buckingham Avenue, Slough, Berkshire SL1 4NL, UK.
| Br J Cancer. 2005 Feb 28;92(4):722-8.
DOI Direct Link |
XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro.
Recent reports suggest that elevated levels of plasminogen activator... | 27th October, 2004
| Xenova Ltd,
| Anticancer Drugs. 2004 Jan;15(1):37-44.
|
Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.
In our continued effort to identify selective MRP1 modulators, we have... | 24th April, 2004
| Department of Medicinal Chemistry, Department of Pharmacology, Analytical
| J Med Chem. 2004 Mar 11;47(6):1339-50.
DOI Direct Link |
Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.
Multidrug resistance mediated by P-glycoprotein (Pgp) or... | 24th April, 2004
| Department of Medicinal Chemistry, Department of Pharmacology, and
| J Med Chem. 2004 Mar 11;47(6):1329-38.
DOI Direct Link |
→View more Xenova research publications. |
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 13 individuals from Xenova using this service.
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 244 times since April 2007, the link to the organisation's website has been followed 52 times
Recent Search Terms used to find this page: xenova | xenova | Xenova.com | Xenova.com | xenova ltd celtic | xenova | xenova revenues | .
Search for more companies in Slough
Search for more companies in Berkshire
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Xenova
